Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Current Drug Metabolism|March 15, 2011
Regulation of hepatic cytochromes p450 by lipids and cholesterolMateja Hafner, Tadeja Rezen, Damjana RozmanDrug Metabolism Reviews|September 6, 2007
Functional genomics approaches to studies of the cytochrome p450 superfamilyTadeja Rezen, Juan A Contreras, Damjana RozmanJournal of Molecular Evolution|September 24, 2004
New aspects on lanosterol 14alpha-demethylase and cytochrome P450 evolution: lanosterol/cycloartenol diversification and lateral transferTadeja Rezen, Natasa Debeljak, Dusan Kordis, et al.Biochimica Et Biophysica Acta|June 24, 2010
Interplay between cholesterol and drug metabolismTadeja Rezen, Damjana Rozman, Jean-Marc Pascussi, et al.Endocrinology|August 27, 2005
Cholesterogenic lanosterol 14alpha-demethylase (CYP51) is an immediate early response geneMartina Fink, Jure Acimovic, Tadeja Rezen, et al.Pharmacogenetics and Genomics|August 27, 2011
The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin actionMateja Hafner, Peter Juvan, Tadeja Rezen, et al.BMC Genomics|August 21, 2009
Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse liversTadeja Rezen, Viola Tamasi, Anita Lövgren-Sandblom, et al.Molecular Nutrition & Food Research|August 4, 2011
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductaseDaniel J Conklin, Russell A Prough, Peter Juvan, et al.BMC Genomics|February 12, 2008
The Sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeostasis and drug metabolismTadeja Rezen, Peter Juvan, Klementina Fon Tacer, et al.Toxicology and Applied Pharmacology|December 26, 2009
Acrolein consumption induces systemic dyslipidemia and lipoprotein modificationDaniel J Conklin, Oleg A Barski, Jean-Francois Lesgards, et al.Pageof 2